share_log

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival As Either Monotherapy Or In Combination With Pembrolizumab In Patients With Relapsed, Refractory, Metastatic Solid Tumor Cancers

Benzinga Real-time News ·  Nov 11, 2022 07:06

Patients Receiving INT230-6 Alone (n=64) had a Median Overall Survival (mOS) of 373 Days

Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors

Combined with Pembrolizumab in a Population Consisting of Heavily Pretreated Patients with Primarily Pancreatic, Bile Duct, Colorectal, and Triple Negative Breast Cancer (n=24), Whose Cancer Progressed, the mOS was 205 Days

Full Set of Results to be Presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment